PSA-Induced Stage Migration Has Ended

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 4
Volume 16
Issue 4

The number of early stage prostate cancers being detected by PSA screening appears to have leveled off; similarly, the gains in cure rates due to early detection may have reached their limit.

ORLANDO—The number of early stage prostate cancers being detected by PSA screening appears to have leveled off; similarly, the gains in cure rates due to early detection may have reached their limit. "It is still crucial for men to have their PSA levels tested, but the days of improved cure rates because of increased detection of organ-confined disease have ended," senior investigator Eric A. Klein, MD, said at ASCO's 2007 Prostate Cancer Symposium (abstract 30). Dr. Klein, professor of surgery and head of urologic oncology, Glickman Urological Institute, Cleveland Clinic Foundation, presented the poster for lead investigator Fei Dong, a second-year medical student at Case Western Reserve University.

"When PSA testing was first introduced in 1987," Dr. Klein said, "most prostate cancers didn't seem to be curable even though the men were treated with radiation and surgery. After 10 years of PSA screening, we were curing more men, but it wasn't because we were doing better surgery or radiation. It was because newly diagnosed prostate cancer was being picked up at a curable stage, and that is what has fueled the increase in cure rates, to about 95%."

The investigators analyzed the surgical pathology of 3,364 patients treated consecutively at the Cleveland Clinic from 1987 to 2005 for extraprostatic extension (EPE), organ-confined disease, and clinically insignificant disease. They also examined 2,256 specimens removed between 1999 and 2005 for clinically insignificant disease, which they defined as tumors less than 0.5 cc, surgical Gleason grade 6 or less, and no EPE.

From 1987 to 2005, pathologic staging showed a decreasing trend for EPE and an increasing trend for organ-confined disease. The percentage of tumors with EPE decreased from 79% to 25% (P <.0001), while organ-confined disease increased from 21% to 75% (P < .0001). However, this positive trend stabilized between 1998 and 2005. In that period, the percentage of organ-confined tumors fluctuated between 63% and 75%, while the proportion of prostate tumors with EPE ranged from 25% to 36%.

The findings suggest that the reservoir of undetected prostate cancers may be depleting and that the current rate of detection may more accurately reflect the true incidence of disease, Dr. Klein said.

"PSA-induced clinical and pathological stage migration appears to have plateaued about 8 years ago," he commented. "It hasn't completely flattened out, but it has slowed substantially. This means that improved rates of cure because of an increase in the likelihood of having organ-confined disease has ended. We're not going to see gains in cure rates beyond what we've already achieved simply based on PSA screening. Increments in cure to 100% will require true, new therapeutic advances both in surgery and radiation therapy."

Related Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content